Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration
Designation follows recent FDA award of Rare Pediatric Disease Designation to Sensorion for OTOF-GT program Sensorion is on track to file a CTA for OTOF-GT in H1 2023 Regulatory News: